CLINICAL TRIALS PROFILE FOR SUNOSI
✉ Email this page to a colleague
All Clinical Trials for SUNOSI
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04602936 ↗ | Solriamfetol in Binge Eating Disorder | Not yet recruiting | Jazz Pharmaceuticals | Phase 4 | 2020-11-15 | The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating disorder (BED). |
NCT04602936 ↗ | Solriamfetol in Binge Eating Disorder | Not yet recruiting | Lindner Center of HOPE | Phase 4 | 2020-11-15 | The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating disorder (BED). |
NCT04622293 ↗ | A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | Not yet recruiting | Rochester Center for Behavioral Medicine | Phase 4 | 2021-04-01 | This study is an 8-week single center, randomized, double-blind, placebo-controlled, flexible titration trial evaluating the efficacy of solriamfetol in the treatment of fatigue symptoms in adult patients with chronic fatigue syndrome. Subjects will be randomized to a solriamfetol group or placebo group. The investigators will utilize an intent to treat model and impute data. The overall goal of this study is to determine the efficacy and effectiveness of solriamfetol for treating chronic fatigue syndrome. |
NCT04788953 ↗ | Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder | Recruiting | Jazz Pharmaceuticals | Phase 4 | 2021-07-21 | In this research study the investigators want to learn more about whether the medication Solriamfetol improves daytime sleepiness in workers who start work at very early times (between 3 and 6am). |
NCT04788953 ↗ | Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder | Recruiting | Charles Andrew Czeisler, MD, PhD | Phase 4 | 2021-07-21 | In this research study the investigators want to learn more about whether the medication Solriamfetol improves daytime sleepiness in workers who start work at very early times (between 3 and 6am). |
NCT05008341 ↗ | Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration | Recruiting | Jazz Pharmaceuticals | Phase 4 | 2021-08-27 | The purpose of study JZP110-401 is to evaluate solriamfetol pharmacokinetics (PK) in the breast milk and plasma of healthy postpartum women following the administration of the drug. The study also aims to estimate the potential daily solriamfetol dose received by the infant from the breast milk of the nursing mother. The safety and tolerability of single oral doses of solriamfetol will also be assessed. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SUNOSI
Condition Name
Clinical Trial Locations for SUNOSI
Trials by Country
Clinical Trial Progress for SUNOSI
Clinical Trial Phase
Clinical Trial Sponsors for SUNOSI
Sponsor Name